Technical Analysis for RDHL - Redhill Biopharma Ltd.
|Grade||Last Price||% Change||Price Change|
RDHL closed up 0.58 percent on Friday, January 18, 2019, on 40 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Down||Flat|
|See historical RDHL trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Stochastic Sell Signal||Bearish||0.00%|
|Jan 18||Hammer Candlestick||Bullish||0.00%|
|Jan 18||Weak + Overbought||Other||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 17||50 DMA Resistance||Bearish||0.58%|
|Jan 17||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.58%|
|Jan 17||Weak + Overbought||Other||0.58%|
|Jan 17||Outside Day||Range Expansion||0.58%|
|Jan 17||Wide Bands||Range Expansion||0.58%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RDHL news...
|52 Week High||11.49|
|52 Week Low||4.4|
|200-Day Moving Average||7.3762|
|50-Day Moving Average||7.1122|
|20-Day Moving Average||6.271|
|10-Day Moving Average||6.882|
|Average True Range||0.4188|
|Chandelier Exit (Long, 3 ATRs )||5.9236|
|Chandelier Exit (Short, 3 ATRs )||6.3864|
|Upper Bollinger Band||7.6407|
|Lower Bollinger Band||4.9013|
|Percent B (%b)||0.73|
|MACD Signal Line||-0.0914|
|Market Cap||118.25 Million|
|Num Shares||17.2 Million|
|Price-to-Earnings (P/E) Ratio||-2.80|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.31|
|Resistance 3 (R3)||7.28||7.11||7.24|
|Resistance 2 (R2)||7.11||7.00||7.13||7.22|
|Resistance 1 (R1)||7.00||6.94||6.92||7.03||7.19|
|Support 1 (S1)||6.72||6.72||6.64||6.75||6.59|
|Support 2 (S2)||6.55||6.66||6.57||6.56|
|Support 3 (S3)||6.44||6.55||6.54|
|Support 4 (S4)||6.47|